GLP-1 receptor agonists and dry eye in adults with type 2 diabetes and obesity
Official title: Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity
Run by Attikon Hospital · NCT07605572 · Data updated 2026-11-12
This study tests whether GLP-1 receptor agonists affect dry eye disease in adults with type 2 diabetes and obesity.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Attikon Hospital Academic / other |
| Locations | 1 site (Athens) |
| Status | Recruiting |
| Started | March 1, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | February 28, 2027 |
| Registry record updated | June 2, 2026 |
| Trial ID | NCT07605572 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with type 2 diabetes and obesity who have not previously used GLP-1 receptor agonists and can provide informed consent.
✕Probably not a fit
Patients with active intraocular inflammation, recent eye surgery, or conditions listed in the exclusion criteria may not experience benefit related to dry eye outcomes.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort follows adults with type 2 diabetes and obesity to see how GLP-1 receptor agonists relate to the presence and severity of dry eye disease. The study is prospective and does not specify an interventional protocol. Researchers will compare ocular surface outcomes before and after exposure to GLP-1 receptor agonists in eligible participants, while accounting for relevant ocular and systemic factors. Inclusion requires adults 18 or older who have not previously used GLP-1 receptor agonists, with informed consent. Exclusion criteria include pregnancy, significant hypoglycemia history, active intraocular inflammation, recent eye surgery, ketoacidosis history, and corneal transplant history. Lead sponsorship is from Attikon Hospital, with collaboration at a center in Athens, Greece.
Why it matters
Potential benefit: If GLP-1 receptor agonists influence ocular surface biology, this could inform personalized treatment considerations for dry eye in patients with diabetes and obesity.
How similar studies have gone: Previous research has documented links between diabetes, obesity, and dry eye, and this study explores a novel angle by examining GLP-1 receptor agonists’ association with ocular surface outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years. 2. Patients who have not previously received GLP-1 receptor agonists (GLP-1 RAs). 3. Patients able to provide informed consent for participation in the study. Exclusion Criteria: 1. Pregnant or breastfeeding patients. 2. History of multiple severe hypoglycemic episodes within the past two years. 3. Active intraocular inflammation in either eye, such as infectious conjunctivitis, keratitis, scleritis, endophthalmitis, or autoimmune uveitis. 4. Patients who have undergone cataract surgery or vitrectomy within the past 6 months. 5. History of ketoacidosis or metabolic acidosis. 6. History of corneal transplantation.
Where it's running
-
2nd Department of Internal Medicine, Research Institute and Diabetes Center, National and Kapodistrian University of Athens, Athens, GRC.
Athens, Greece Recruiting
Study contacts
- Study coordinator: Vaia Lambadiari, MD, PhD
- Email: vlambadiari@gmail.com
- Phone: (0030)2105838000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Differentiating heart disease in autoimmune vs. type 2 diabetes
This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.
-
Can cyclosporine 0.1% eye drops improve comfort for contact lens wearers with dry eye
This study tests whether a water-free cyclosporine eye drop (VEVYE) can reduce dry eye symptoms and improve comfort for adults who wear soft contact lenses.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
-
Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease
This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.
-
Association Between Periodontitis and Dry Eye Disease in Adults
This study tests whether periodontitis and dry eye disease are linked by comparing groups with and without each condition.
-
Reset-INSPIRE: See if CGM can reveal insulin sensitivity in people at risk for MASLD
This study tests whether real-time CGM data can accurately reflect insulin sensitivity in adults without diabetes who are at risk for MASLD.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.